Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin.
Xiufen LiuMasanori OndaNathan WatsonRaffit HassanMitchell HoTapan K BeraJunxia WeiAnirban ChakrabortyRichard BeersQi ZhouAsif ShajahanParastoo AzadiJingyu ZhanDi XiaIra H PastanPublished in: Proceedings of the National Academy of Sciences of the United States of America (2022)
SignificanceMesothelin (MSLN) is a cell-surface protein that is a popular target for antibody-based therapies. We have identified shed MSLN as a major obstacle to successful antibody therapies and prepared a monoclonal antibody that inhibits shedding and makes very active CAR T cells whose activity is not blocked by shed MSLN and merits further preclinical development.